Clinical Trials

15 enrolled 20 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01223898 2020-12-09

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

19 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01456676 2020-12-09

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

11 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00135005 2020-12-08

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

59 enrolled

Gastrointestinal Stromal Tumors

NCT00384228 2020-12-08

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Phase 1/2 Completed

42 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01279473 2020-12-08

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Phase 1/2 Completed

42 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00471497 2020-11-18

ENESTnd

846 enrolled 33 charts

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT01274351 2020-09-01

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

112 enrolled 11 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01744665 2020-03-10

ENESTgoal

59 enrolled 18 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02272777 2019-08-19

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

225 enrolled 7 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02253277 2019-05-01

CoRNea

5 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00633295 2017-06-22

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

9 enrolled

Gastrointestinal Stromal Tumors

NCT00264160 2017-03-06

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Phase 2/3 Completed

36 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01110668 2017-02-28

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

2 enrolled

Disease Progression, Gastrointestinal Stromal Tumors

NCT01126892 2017-02-28

ENACT

6 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01061177 2017-02-24

'MACS1252

Other hematologic neoplasm

1,090 enrolled 24 charts

Leukemia, Philadelphia Chromosome

NCT00718562 2017-02-23

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

35 enrolled

Gastrointestinal Stromal Tumors

NCT00786812 2017-02-23

MACS0439

89 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01289028 2017-01-02

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

125 enrolled 11 charts

Neoplasms, Gastrointestinal Stromal Tumors

NCT01368523 2016-11-16

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

19 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00760877 2016-11-08

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

207 enrolled 9 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00785785 2016-06-16

ENESTg1

644 enrolled 8 charts

Gastrointestinal Stromal Tumors

NCT02733445 2016-04-11

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Completed

2,650 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01043874 2016-04-08

MACS0911

45 enrolled 9 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01275196 2016-04-08

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

267 enrolled 17 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01254188 2016-03-03

ENESTxtnd

421 enrolled 14 charts

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01227577 2016-02-08

MACS1428

128 enrolled 11 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01028222 2015-12-30

TEAM

55 enrolled 13 charts

Dermatologic

Melanoma

NCT00802841 2015-11-16

LASOR

191 enrolled 13 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01220648 2015-05-05

NICOLI

4 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

14 enrolled

Neoplasms, Gastrointestinal Stromal Tumors

NCT00471328 2012-06-12

ENEST

248 enrolled 17 charts